Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)

LONDON and OXFORD, England, March 15, 2010 - Matrix Corporate Capital ("Matrix") and PharmaVentures Limited
("PharmaVentures") today announced the signing of a Memorandum of
Understanding ("MOU") covering strategic transactions in the biotech,
pharmaceutical and med tech sectors. The companies will work together to
identify licensing, buyout, investment, IPO and consolidation opportunities
which bring together both strategic expertise and capital from Europe's
dedicated healthcare investors.

The MOU joins two firms with synergistic transactional
capabilities in the healthcare life sciences space:

Matrix is a provider of a full range of corporate finance
services to small and mid cap growth companies. They are able to service
companies across the full corporate lifecycle, with access to financing from
Series A venture finance through IPO, secondary placements and traded debt.

PharmaVentures is a leading specialist healthcare business
advisory group assisting corporations in all aspects of strategic
transactions, from strategy formulations to implementation. PharmaVentures
has an extensive track record of successful strategic advisory mandates in
the sector with over 17 years of experience and 450 assignments, for over 600
clients, in 38 countries.

Fintan Walton, Chief Executive of PharmaVentures said "For our
clients our alliance with Matrix will create one of Europe's strongest teams
in healthcare transactions and equity financing. Our clients have always
demanded the best and a strong experienced healthcare team is essential to
their own success. Matrix has excellent proven capabilities in corporate
finance and we are delighted to have entered into this agreement."

Malcolm Le May, Chief Executive of Matrix Corporate Capital
said "We are delighted to team our skills with those of PharmaVentures. It
has an excellent track record with some of the largest names in the
pharmaceutical sector. Many of these companies now face unprecedented change
in their business models, with the pursuit of greater efficiency driving
buyouts; assets sales and licensing. Matrix has access to both private and
public sector-specific capital across Europe which, with PharmaVentures'
help, will allow us to create innovative transactions around these assets."

About Matrix Group

Matrix Corporate Capital is part of Matrix Group which is a privately
owned financial services business founded in 1987 other areas of expertise
include Asset Management, Property, and Specialised Finance.To date Matrix
has raised around GBP8 billion for its investment products and currently has
circa GBP3 billion of funds under management. Matrix's staff of over 200 are
based in the West End of London at One Vine Street. Matrix Group Limited is
the holding company for the following business activities

About PharmaVentures

PharmaVentures Limited (www.pharmaventures.con) is
based in Oxford, England and is a leading international corporate advisory
firm supporting its clients' growth ambitions through licensing, joint
ventures and M&A in the healthcare industry. The company works for a variety
of clients from start-ups to global pharmaceutical corporations, their
advisors, investment companies and government bodies. It also produces the
highly popular PharmaDeals(R) range of intelligence products including
analysis tools and reports. In 2006 it launched the world's first dedicated
online pharmaceutical television channel PharmaTelevision(R) (
www.pharmatelevision.com)

    Contact

    Matrix Corporate Capital LLP
    Steve Cox, Partner
    +44-203-206-7000

    PharmaVentures Limited
    Tibor Papp
    +44(0)1865-332700

Contact: Matrix Corporate Capital LLP, Steve Cox, Partner, +44-203-206-7000; PharmaVentures Limited, Tibor Papp, +44(0)1865-332700